RNAZ Valuation
Transcode Therapeutics Inc
$
11.200
RNAZ Relative Valuation
RNAZ's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RNAZ is overvalued; if below, it's undervalued.
Historical Valuation
Transcode Therapeutics Inc (RNAZ) is now in the Fair zone, suggesting that its current forward PS ratio of 11.20 is considered Fairly compared with the five-year average of -1.87. The fair price of Transcode Therapeutics Inc (RNAZ) is between 7.44 to 54.37 according to relative valuation methord.
Relative Value
Fair Zone
7.44-54.37
Current Price：11.20
Fair
-8.60
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Transcode Therapeutics Inc. (RNAZ) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-0.15
EV/EBIT
Transcode Therapeutics Inc. (RNAZ) has a current EV/EBIT of -0.15. The 5-year average EV/EBIT is -0.54. The thresholds are as follows: Strongly Undervalued below -3.72, Undervalued between -3.72 and -2.13, Fairly Valued between 1.04 and -2.13, Overvalued between 1.04 and 2.63, and Strongly Overvalued above 2.63. The current Forward EV/EBIT of -0.15 falls within the Historic Trend Line -Fairly Valued range.
11.20
PS
Transcode Therapeutics Inc. (RNAZ) has a current PS of 11.20. The 5-year average PS is 8.84. The thresholds are as follows: Strongly Undervalued below -31.65, Undervalued between -31.65 and -11.41, Fairly Valued between 29.08 and -11.41, Overvalued between 29.08 and 49.33, and Strongly Overvalued above 49.33. The current Forward PS of 11.20 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Transcode Therapeutics Inc. (RNAZ) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.30. The thresholds are as follows: Strongly Undervalued below -1.45, Undervalued between -1.45 and -0.87, Fairly Valued between 0.28 and -0.87, Overvalued between 0.28 and 0.86, and Strongly Overvalued above 0.86. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.76
P/FCF
Transcode Therapeutics Inc. (RNAZ) has a current P/FCF of -0.76. The 5-year average P/FCF is -0.55. The thresholds are as follows: Strongly Undervalued below -2.91, Undervalued between -2.91 and -1.73, Fairly Valued between 0.64 and -1.73, Overvalued between 0.64 and 1.82, and Strongly Overvalued above 1.82. The current Forward P/FCF of -0.76 falls within the Historic Trend Line -Fairly Valued range.
Transcode Therapeutics Inc (RNAZ) has a current Price-to-Book (P/B) ratio of 1.52. Compared to its 3-year average P/B ratio of -0.17 , the current P/B ratio is approximately -977.25% higher. Relative to its 5-year average P/B ratio of 0.27, the current P/B ratio is about 458.78% higher. Transcode Therapeutics Inc (RNAZ) has a Forward Free Cash Flow (FCF) yield of approximately -153.83%. Compared to its 3-year average FCF yield of -533.62%, the current FCF yield is approximately -71.17% lower. Relative to its 5-year average FCF yield of -378.37% , the current FCF yield is about -59.34% lower.
1.52
P/B
Median3y
-0.17
Median5y
0.27
-153.83
FCF Yield
Median3y
-533.62
Median5y
-378.37
Competitors Valuation Multiple
The average P/S ratio for RNAZ's competitors is 5.29, providing a benchmark for relative valuation. Transcode Therapeutics Inc Corp (RNAZ) exhibits a P/S ratio of 11.20, which is 111.82% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of RNAZ increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of RNAZ in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is Transcode Therapeutics Inc (RNAZ) currently overvalued or undervalued?
Transcode Therapeutics Inc (RNAZ) is now in the Fair zone, suggesting that its current forward PS ratio of 11.20 is considered Fairly compared with the five-year average of -1.87. The fair price of Transcode Therapeutics Inc (RNAZ) is between 7.44 to 54.37 according to relative valuation methord.
What is Transcode Therapeutics Inc (RNAZ) fair value?
How does RNAZ's valuation metrics compare to the industry average?
What is the current P/B ratio for Transcode Therapeutics Inc (RNAZ) as of Nov 03 2025?
What is the current FCF Yield for Transcode Therapeutics Inc (RNAZ) as of Nov 03 2025?
What is the current Forward P/E ratio for Transcode Therapeutics Inc (RNAZ) as of Nov 03 2025?